Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia (Q46341511)

From Wikidata

Jump to navigation Jump to search

scientific article published on 5 December 2012

Language	Label	Description	Also known as
English	Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia	scientific article published on 5 December 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

21

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

24

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

Thomas Burmeister

object named as

T Burmeister

9

0 references

Martin Bornhäuser

5

object named as

M Bornhäuser

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

author name string

H Pfeifer

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

B Wassmann

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

W Bethge

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

J Dengler

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

M Stadler

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

D Beelen

7

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

V Vucinic

8

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

M Stelljes

10

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

C Faul

11

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

P Dreger

12

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

A Kiani

13

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

K Schäfer-Eckart

14

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

R Schwerdtfeger

15

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

E Lange

16

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

B Kubuschok

17

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

H A Horst

18

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

M Gramatzki

19

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

P Brück

20

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

D Hoelzer

22

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

N Gökbuget

23

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

GMALL Study Group

25

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

publication date

5 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

27

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

1254-1262

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph ) acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults.

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction.

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Early molecular response to posttransplantation imatinib determines outcome in MRD Philadelphia-positive acute lymphoblastic leukemia (Ph ALL).

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Cellular therapy: donor lymphocyte infusion

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib.

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph ALL)

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph ALL)

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL)

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

21 January 2018

Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL).

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

7 January 2021

based on heuristic

inferred from DOI database lookup

Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2012.352

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2012.352

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23212150

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46341511&oldid=2207808753"